Im­mat­ics an­nounces mul­ti­ple pipeline changes with lat­est fi­nan­cial re­sults

The T-cell biotech Im­mat­ics is look­ing to make some changes to its pipeline.

Im­mat­ics re­leased its 2022 fi­nan­cial re­sults on Tues­day and an­nounced that it’s plan­ning to dis­con­tin­ue its pro­gram for IMA201, an ex­per­i­men­tal cell ther­a­py for sol­id tu­mors that ex­press the anti­gens known as MAGE4/8. It plans to shift fo­cus to IMA401, a TCR bis­pe­cif­ic which goes af­ter the same tar­get. IMA401 al­so has bet­ter po­ten­cy and was de­vel­oped more re­cent­ly ac­cord­ing to Im­mat­ics CEO Harpreet Singh, in an in­ter­view with End­points News. 

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN